CONCLUSIONS
Selnoflast 450 mg QD administered over 7 consecutive days was well‐tolerated and achieved the plasma and tissue exposure predicted to maintain the targeted level of NLRP3 inflammasome inhibition. However, histological analysis, expression of an IL‐1 gene signature in sigmoid colon tissue and additional biomarker analyses showed no robust differences between treatment arms, suggesting that no major therapeutic effects are to be expected in UC.